Renown Health Board Of Directors Chair, Jim Devolld, Receives Nevada Hospital Association's Commitment To Community Award For Trustee Excellence Award
Renown Health Board of Directors Chair, Jim DeVolld, Receives Nevada Hospital Association’s Commitment to Community Award for Trustee Excellence Award Renown Health Board of Directors Chair, Jim DeVolld has been awarded the prestigious 2019 Commitment to Community Award for Trustee Excellence from the Nevada Hospital Association (NHA). Each year at the association’s annual meeting, the Nevada Hospital Association publicly acknowledges one trustee who exemplifies exceptional leadership and the characteristics to which all hospital and health system Board leaders should aspire, including: Professional excellence Outstanding achievements Innovative accomplishments Extraordinary compassion in caring for the community Success in overcoming barriers, and Exemplary contributions to effectively advocate on behalf of hospitals, patients, and the healthcare system. “Jim DeVolld’s personal connection and passion for improving the community’s overall health are what drive his commitment to the Renown Health Board,” NHA’s President & CEO, Bill Welch said. “Under Jim’s leadership, Renown Health is nationally recognized for top levels of quality and safety, most notably through advances made in clinical care, the adoption of health information technology and the development of team-based and patient-centered medical homes.” DeVolld was nominated by President & CEO of Renown Health, Anthony D. Slonim, MD, D.Ph. and his senior leadership team at Renown Health. Through Jim and the Boards’ support, the integrated healthcare system now includes four hospital campuses, 120 sites of primary, urgent and specialty care, affiliations with Stanford Medicine, the University of Nevada-Reno Medical School, St. George’s University in Grenada (SGU) School of Medicine, and a health plan, Hometown Health that serves more than 180,000 members. Renown Health’s more than 7,000 employees and 800 providers serve as the regional referral care center for over 100,000 square miles, from Sacramento to Salt Lake City. An essay was submitted describing DeVolld’s leadership of the 43 member Renown Health Board of Directors with deep admiration and chronicled a long list of organizational accomplishments. One nominee stated, “Jim sets a stellar example as a Board Chair who tirelessly advocates for improvement, inclusion, responsibility, preparation, taking the ‘high road,’ and the importance of collaborative, positive relationships. Jim’s commitment has extended beyond traditional healthcare to include economic health and community health and well-being. "A lifelong Nevadan, Jim DeVolld grew up in Yerington before moving to Reno 31 years ago. Jim DeVolld’s32-year-old daughter was born at Renown Regional Medical Center and his family receives care at Renown Health. Jim DeVolld’s personal connection and passion for improving the community’s overall health are what drive his commitment to the Renown Health Board. To ensure the world-class care our community expects and deserves, he has focused first on caring for Renown’s 7,000 employees who provide outstanding care every day. After eight years serving in various roles with Renown Health’s board of directors, Jim DeVolld, managing director, commercial banking at First Independent Bank, was elected as the chairman of the board, Renown Health for a two-year term, effective January 1, 2019. Renown’s four governing boards serve a key role in achieving Renown’s mission of making a genuine difference in the health and well-being of the people and communities in Northern Nevada. Board members help guide the health system with the charitable mission of “making a genuine difference in the health and well-being,” based on the principles of caring, integrity, collaboration and excellence. Jim DeVolld has spent decades working in the Northern Nevada banking industry. He also serves as chairman of the Nevada Tax Commission and is a board member of the Boys and Girls Club of Truckee Meadows. About the NHA The Nevada Hospital Association is a not-for-profit, statewide trade association representing Nevada’s acute care hospitals along with psychiatric, rehabilitation and other specialty hospitals as well as health related agencies and organizations throughout the state. Allied with the American Hospital Association, the NHA is an independent organization headquartered in Reno, Nev. About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org.
Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.” About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org and follow Dr. Tony Slonim on Twitter @RenownCEOTonyMD. About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.Additional Media Contact:Sung Lee, Investors 650-524-7792Arran Attridge, Media 650-425-8975